Key points – JAK1/2 inhibitor treatment in myelofibrosis is associated with an increased risk for aggressive B-cell lymphomas. Patients at risk have a pre-existing B-cell clone in their bone marrow which can be identified by PCR. (Abstract only)
Home / Resource Library / Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy